Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
gptkb:nivolumab
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC11
|
| gptkbp:CASNumber |
477202-00-9
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:firstBook |
yes
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:ipilimumab
|
| gptkbp:halfLife |
15.4 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Yervoy
|
| gptkbp:indication |
colorectal cancer
melanoma renal cell carcinoma |
| gptkbp:KEGGID |
D09716
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CTLA-4 inhibitor
|
| gptkbp:MedlinePlusID |
a611016
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
CHEMBL1201834
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
fatigue pruritus rash inflammatory bowel disease endocrinopathies |
| gptkbp:UNII |
83HN0GTJ6D
|
| gptkbp:bfsParent |
gptkb:Bristol_Myers_Squibb
gptkb:百时美施贵宝 gptkb:Bristol-Myers_Squibb |
| gptkbp:bfsLayer |
6
|